Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
07 March 2013
(221.11 Kb 4 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013